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uith the explosive growth in percu-
taneous interventions and their rela-
tive success, an increasingly large
number of patients are carrying intra-
ascular devices. Moreover, successful interven-
ion, coupled with other advances in therapy,
as lengthened the useful in-vivo “life time” of
uch devices. Thus, patients are being exposed
o complicated device– drug combination plat-
orms (DDCPs) for increasingly longer periods
f time. At the same time, these devices are
etting more complicated; drug–platform–device
ombinations often introduce previously unantici-
ated or uncharacterized clinical and pathological
henomena beyond what a drug or device can
ause by itself. This is especially true when the
rug has a different purpose (e.g., reduce injury,
epair induced restenosis) than the device alone
cause vascular injury). In addition, the bridge be-
ween the two (polymer or other platforms) can
nduce its own set of problems such as inflamma-
ion and nonphysiololgical local concentrations or
elease kinetics of the drug. All of these factors
re starting to reveal a new natural/unnatural his-
ory in patients with coronary artery disease (1);
ome changes are quite different from what was
nown until now and indeed, some of that was
ot anticipated from or revealed in extensive pre-
linical animal studies—the current de facto cor-
erstone of a drug’s regulatory journey. Therefore,
t stands to reason that this changing natural his-
ory should also radically change our approach to-
ards anticipating, predicting, detecting, and in-
erdicting the new clinical complications that are
nfolding. One could make a case for an increas-f
rom the *University of Minnesota, Minneapolis, Minneapolis, Minne-
ota; and the †University of California Irvine, Irvine, California.ng role for powerful imaging modalities in this
cenario.
All of the regulatory agencies require rigor-
us pre-clinical animal studies under good labo-
atory practice conditions. Multiple time points
p to 6 months are needed under U.S. and Eu-
opean regulations (2). The choice of an animal
odel is left to investigators but this is not al-
ays a simple and straightforward decision.
igs, dogs, and, to a lesser extent, primates are
he most often studied models for evaluating
oronary stents. Each of these models has sig-
ificant limitations, but the pig is thought to be
he model most close to human stent patho-
hysiology. Unfortunately, while accepted as a
est consensus model (3), evaluating a stent in
normal porcine artery is completely different
rom the biology of a stent in an atherosclerotic
uman coronary artery. Rigorous comparative
tudies between stent behavior in pigs and hu-
ans are lacking but some disadvantages are
uite obvious. The time course of healing is
uite different between pigs and humans (4).
he influence of irregular plaque geometry on
n vivo strut anatomy (and thus the repair re-
ponse) is not clear from animal studies (5).
he impact of clinical scenarios like compliance
ith antiplatelet therapy, risk factor profile, and
ytokinemia/peri-surgical stress cannot be eval-
ated easily in animal studies; such phenome-
on have important clinical correlates and in-
ammation has been shown to increase tissue
actor levels and possibly can augment throm-
ogenecity of drug-eluting stents (DES) (6).
inally, there is a trend among toxicologists to
tilize increasingly smaller numbers of animals
or research (7), and this might reduce the
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671ower of detecting crucial evidence in animals
ith complex device– drug implants.
Not surprisingly, questions have been raised
hether animal data can predict natural history
n humans (8) and there is some data with
ES that short to intermediate results in pigs
ight not be concordant with results in hu-
ans at similar time points (8). Healing occurs
ore rapidly in healthy porcine arteries com-
ared with diseased human lesions. Thus, a
egative result in pigs (more tissue prolifera-
ion) at 6 months might not necessarily mean
here is no benefit in humans in a comparative
ime frame. Conversely, adequate healing in the
hort to intermediate time frame in animal
odels does not necessarily mean similar effi-
acy in human models at comparable time
oints; indeed, the DES experience in humans
llustrates some of this discordance. As pointed
ut in the consensus document (3), true efficacy
nd safety can only be proven in man. With all
f these uncertainties, it is quite surprising that
dditional tools to refine in vivo risk and risk
rediction, have not received greater attention.
At the other end, possibly offering greater
ertainty, is a process involving long-term post-
arketing clinical follow-up. This strategy has
een used with some success with drugs and
ow, following unexpected and costly debacles,
s being considered for devices (9). This model,
hile reassuring, has tremendous costs; since
vents have to happen for them to be detected, it
ntails a significant cost in terms of human mis-
ry. In addition, it also remains open ended—we
o not know if and/or when events will occur in
he natural history of the device. This strategy
s likely to be inefficient; events, while of high
mpact, are likely to be rare, and thus a large
umber need to be followed to detect these few
vents. This entails economic and opportunity
osts to society and a “product uncertainty” cost
o the industry.
Imaging is a powerful medium and its reach
s rapidly and progressively extending into un-
erstanding structure and function at an organ,
issue, cell, and molecular level. While the biol-
gy of DDCPs is complex, most of its adverse
henomenon described so far are rather ex-
ected or could be anticipated. End points, like tessel structure, degree of proliferative repair,
issue composition (lipid deposition, neointima
r thrombus formation, smooth muscle cell/fi-
rous tissue proliferation) and flow limitation,
an be seen to varying degrees using commonly
vailable instrumentation and expertise. End or-
an effects, like microvascular flow, distal em-
olization, and infarction, can be seen and
uantitated. Some more invasive techniques are
ow showing active biology of tissue–stent in-
eractions; one such study in this issue of
JACC, by Higo et al (10), provides an interest-
ng insight into the biology of DES–tissue in-
eraction. Using angioscopy at 2 time points 10
onths apart following coronary stenting, they
ound that DES-induced neointima is associ-
ted with lipid-laden regions of new atheroma
unrelated to the original atheromatous lesion)
n some regions in proximity to the stent.
ther regions, with the usual white neointima,
id not show excess of lipid accumulation. In-
erestingly, regions with lipid-laden neointima
ere significantly more thrombogenic than ar-
as with white neointima. Bare-metal stents
ere not associated with such changes. This
uggests that absence of a healthy endothelial
arrier can allow lipid transudation and can
ediate accelerated atheroma under a DES. It
s obvious that such invasive methods cannot be
outinely applied to clinical surveillance; never-
heless, it highlights the possibility of what im-
ging can do. With better imaging technology,
ne can envisage noninvasive surveillance to
dentify patients who do not develop an ade-
uate endothelial barrier over a stent or those
hat are in the process of developing a throm-
us before a clinical event happens or those
ho are developing accelerated atheroma with a
igh lipid content (and therefore, portend an
dverse clinical outcome).
Of course, while conceptually appealing, such
nthusiasm about imaging needs to be tem-
ered with the reality of what is available to-
ay. None of the currently effective imaging
echnologies is sufficiently noninvasive for rou-
ine use in monitoring device– drug–tissue in-
eractions. Those that are available are not yet
ully developed and the incremental value of
heir application needs to be defined. Neverthe-
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672ess, imaging is improving and it is just a mat-
er of time before we will be using it for defin-
ng risk and refining success of device– drug
ombination platforms. Initial acceptance is un-
ikely due to regulatory pressure. Voluntary
doption of novel imaging protocols will be
ased on the attractiveness of having a window
nto the future events, ability to offer mechanis-
ic explanation of phenomenon, and the possi-
ility that it might improve device technology.
he greatest amount of adoption will only oc-
ur if imaging can produce viable surrogate end
oints that shorten the costly and often fragile
roduct development cycle for devices, espe-
ially those hitched to “biologics”—a notorious
egulatory minefield.
How would robust imaging technologies best
e utilized in the future? We envisage the fol-
owing model. Market theory suggests that a
evice is likely to follow a journey of 5 stages
Fig. 1). We anticipate a similar model for on-
oing investigation to anticipate and predict
dverse outcomes with device– drug implants.
he proof of concept stage will still depend on
re-clinical animal studies as currently done.
owever, rather than using fixed time points
or a “sacrifice and look” strategy, there will be
need to use imaging to obtain a more “dy-
amic view” of changing vascular biology. This
ill also help define subsets of characteristics
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Broad-based Imaging: 
For Safety & Pathophysiology
Imaging may be used for:
• Structure
• Components (e.g. SMC, Macrophages)
• Pathways (e.g. inflammation, apoptosis)
• Function
• End Organ Effects
Figure 1. Conceptual Model for the Role of Imaging in the Natuhat identify and predict animals with a subop- rimal outcome. Pre-approval clinical studies
phase 2 and possibly substudies of phase 3 tri-
ls for supporting a new device) would incorpo-
ate imaging parameters to identify natural and
nnatural changes to in vivo device-induced biol-
gy in humans. The idea here is that identifying
oncerning changes in the biology of device–
rug–tissue interaction early on might help pre-
ict adverse clinical outcomes down the road. If
hese studies consistently identify high-risk pre-
ictors with any certain device, some form of
oninvasive monitoring might be needed post-
ntroduction (akin to post-market surveillance).
he growth, plateau, and mature stages of the de-
ices’ journey can be limited to surveillance for
linical end points (based on probability) should
he previous investigation reveal no concerning
ndings. Some companies might continue to in-
est in sophisticated imaging in a small subset of
atients, in an effort to eke out some competitive
dge for their DDCP, in the face of multiple other
ew entrants challenging their mature technology.
Of course, these investigatory protocols need to
e carefully thought out, not be smothering in
heir burden, and not delay introduction/percola-
ion of life altering DDCPs. Economics will un-
oubtedly play a role but will eventually be
orked out. Given the magnitude of clinical utili-
ation, unexpected clinical events are likely to
ave a larger economic impact than some upfront
Plateau Maturity
ent Stages
Focused Imaging: 
Probability & Event Driven
Imaging may be needed
No imaging needed
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History of New Drug–Device Combination Platformswth
pmegulatory costs.
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673Imaging is partnering intervention in the clinical
rena and it is but a matter of time that it will
tart to partner in the pre-clinical product devel-
pment arena as well. While clinician-investiga-
ors are likely to be ready to enthusiastically adopt
uch value-added technology, it is less likely that
he regulatory apparatus will be so accepting. It is
ime to start thinking about the changing role of
maging and imaging-related surrogate end points
n the regulatory framework. As imaging technol-
gy continues to mature, we hope our readers, theet al. Drug-eluting stents in preclinical 2002–11.gencies vigorously join us in thoroughly airing
ut this debate. We foresee that sophisticated im-
ging will be the best alternative to an ex vivo ex-
mination.
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